Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Abbreviations: AKT, protein kinase B; ALT, alanine aminotransferase; AMPK, AMP-activated protein kinase; AST, aspartate aminotransferase; ATG16L1, autophagy-related protein 16 to 1; ATG5, autophagy-related protein 5; BALF, bronchoalveolar lavage fluid; BUN, blood urea nitrogen; CAT, catalase; Caspase-3, cysteinyl aspartate-specific proteinase-3; CFU, colony-forming unit; CLP, cecal ligation and puncture; COX-2, cyclooxygenase-2; ERK, extracellular signal-regulated kinase; GSH, glutathione; GSH-Px, glutathione peroxidase; HO-1, heme oxygenase-1; IFN-γ, interferon gamma; IFIH1, interferon induced with helicase C domain 1; IL-1β, interleukin-1 beta; IL-6, interleukin-6; i.m., intramuscular injection; iNOS, inducible nitric oxide synthase; i.p., intraperitoneal injection; i.t., intratracheal instillation; i.v., tail vein injection; LC3-II, microtubule-associated proteins 1A/1B light chain 3B-II; LPS, lipopolysaccharide; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MDA, malondialdehyde; MPO, myeloperoxidase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor kappa B; NO, nitric oxide; Nrf2, nuclear factor erythroid 2-related factor 2; p-AKT, phospho-protein kinase B; p-AMPK, phospho-AMP-activated protein kinase; PA, Pseudomonas aeruginosa; PD-1, programmed cell-death protein 1; PD-L1, programmed death-ligand 1; P-ERK, phospho-ERK; PI3K, phosphoinositide 3-kinase; p-PI3K, phospho-phosphoinositide 3-kinase; p.o., oral gavage; p-mTOR, phospho-mammalian target of rapamycin; SCr, serum creatinine; SIRT1, sirtuin 1; SOD, superoxide dismutase; STAT1, signal transducer and activator of transcription 1; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; VDR, vitamin D receptor; W/D, wet/dry weight ratio.
Source: Study characteristics. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Systematic review.
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The efficacy of artesunate in animal models of sepsis: a systematic review and meta-analysis
Source: Article title.
The efficacy of artesunate in animal models of sepsis: a systematic review and meta-analysis
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The efficacy of artesunate in animal models of sepsis: a systematic review and meta-analysis
Systematic review · Frontiers in Pharmacology · 2026
Original publication title
The efficacy of artesunate in animal models of sepsis: a systematic review and meta-analysis
Copyright © 2026 Xie, Lv, Wang, Wei, Gui, Han, Zhou, Feng and Gu.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
In this study, we aimed to conduct the first systematic review and meta-analysis to evaluate the therapeutic efficacy and underlying mechanisms of AS in animal models of sepsis.
Source: ObjectivesAbstract: What methods does the paper describe?
We systematically searched five electronic databases up to 3 September 2025, for controlled in vivo studies analyzing the effects of AS in septic animals. The study quality was assessed using the SYRCLE risk-of-bias tool, and evidence certainty was rated via the GRADE approach. Statistical analyses, including meta-analysis, publication bias, and sensitivity analyses, were performed using RevMan 5.4 and Stata 17.0.
Source: MethodsAbstract: Systematic Review Registration
Abstract: Results
Fifteen studies involving mice and rats were included. Meta-analysis indicated that AS was associated with improved survival (10 studies, OR: 6.87, 95% CI: 3.81 to 12.41, p < 0.00001), reduced bacterial load, and promotion of body weight recovery. Organ protection was evidenced by attenuated lung injury (reduced histological scores, MPO activity, and wet-to-dry ratio) and improved liver function (decreased AST and ALT levels). Analysis of cytokine data from different time-points suggested a potential phase-dependent immunomodulatory effect: AS suppressed pro-inflammatory cytokines (TNF-α and IL-6) during the hyperinflammatory phase while restoring immune competence in the immunosuppressive phase, accompanied by elevated IL-1β.
Furthermore, AS reduced apoptosis (decreased TUNEL-positive cells) and enhanced pro-survival signaling (increased p-mTOR/mTOR ratio); however, its effect on caspase-3 was not significant. Sensitivity analyses supported the robustness of the primary findings, and no significant publication bias was detected within the limits of the available studies.
Source: ResultsAbstract: Conclusion
AS is associated with survival benefits and multi-organ protection in septic animal models through multimodal mechanisms, potential phase-aware immunomodulation, antiapoptotic effects, and enhanced bacterial clearance. Despite methodological heterogeneity across studies, these preclinical findings support further investigation of AS as a potential therapeutic candidate for sepsis treatment.
Source: ConclusionAuthors’ abstract
Background
Sepsis is a life-threatening condition caused by a dysregulated host response to infection, characterized by biphasic immune dysregulation and high mortality rates. Artesunate (AS), a semisynthetic artemisinin derivative, has demonstrated broad pharmacological properties, yet its overall efficacy and mechanisms in sepsis remain systematically unassessed at the preclinical level.
Objectives
In this study, we aimed to conduct the first systematic review and meta-analysis to evaluate the therapeutic efficacy and underlying mechanisms of AS in animal models of sepsis.
Methods
We systematically searched five electronic databases up to 3 September 2025, for controlled in vivo studies analyzing the effects of AS in septic animals. The study quality was assessed using the SYRCLE risk-of-bias tool, and evidence certainty was rated via the GRADE approach. Statistical analyses, including meta-analysis, publication bias, and sensitivity analyses, were performed using RevMan 5.4 and Stata 17.0.
Results
Fifteen studies involving mice and rats were included. Meta-analysis indicated that AS was associated with improved survival (10 studies, OR: 6.87, 95% CI: 3.81 to 12.41, p < 0.00001), reduced bacterial load, and promotion of body weight recovery. Organ protection was evidenced by attenuated lung injury (reduced histological scores, MPO activity, and wet-to-dry ratio) and improved liver function (decreased AST and ALT levels). Analysis of cytokine data from different time-points suggested a potential phase-dependent immunomodulatory effect: AS suppressed pro-inflammatory cytokines (TNF-α and IL-6) during the hyperinflammatory phase while restoring immune competence in the immunosuppressive phase, accompanied by elevated IL-1β.
Furthermore, AS reduced apoptosis (decreased TUNEL-positive cells) and enhanced pro-survival signaling (increased p-mTOR/mTOR ratio); however, its effect on caspase-3 was not significant. Sensitivity analyses supported the robustness of the primary findings, and no significant publication bias was detected within the limits of the available studies.
Conclusion
AS is associated with survival benefits and multi-organ protection in septic animal models through multimodal mechanisms, potential phase-aware immunomodulation, antiapoptotic effects, and enhanced bacterial clearance. Despite methodological heterogeneity across studies, these preclinical findings support further investigation of AS as a potential therapeutic candidate for sepsis treatment.
Systematic Review Registration
Publication and source details
Original title: The efficacy of artesunate in animal models of sepsis: a systematic review and meta-analysis
Wenzhan Xie; Linxi Lv; Tian Wang; Jialong Wei; Yanshan Gui; Bing Han; Laixian Zhou; Hui Feng; Wei Gu
Frontiers in Pharmacology · 2026
* Correspondence: Hui Feng, huifeng2022@cqu.edu.cn; Wei Gu, guwei@cqu.edu.cn Copyright © 2026 Xie, Lv, Wang, Wei, Gui, Han, Zhou, Feng and Gu.2026Xie, Lv, Wang, Wei, Gui, Han, Zhou, Feng and Guhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was received for this work and/or its publication. This study was supported by the National Natural Science Foundation of China (Nos. 82372549, 82241059, and 82372238) and the Natural Science Foundation of Chongqing, China (No. CSTB2023NSCQ-MSX0482).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:17:35.974251+00:00
DOI: 10.3389/fphar.2026.1748083 · PMC12891116